VetClick
Menu Menu
Login

VetClick

/ News
Friday, 29th March 2024 | 4,186 veterinary jobs online | 103 people actively seeking work | 5,479 practices registered

Veterinary Industry News

Send us your news

Boehringer Launches The ACE Inhibitor Benefortin®

12 years ago
6922 views

Posted
1st March, 2012 17h27


Benefortin Boehringer Ingelheim Vetmedica, has strengthened its position in the cardiology sector with the launch of its new, highly palatable1 ACE inhibitor, Benefortin®, which is licensed for the treatment of congestive heart failure (CHF) in dogs. It is also licensed for the treatment of chronic renal insufficiency (CRI) in cats. Benefortin, which contains benazepril hydrochloride as its active ingredient, uses novel micro-cap technology to mask the taste of the bitter molecule. This ensures that Benefortin tastes good1, even if it is bitten, crunched or chewed. Indeed, taste tests demonstrated that dogs and cats approve wholeheartedly, with 100% palatability in dogs and 92% palatability in cats in home settings1. It is available in 5mg and 20mg tablets for dogs and 2.5mg tablets which are for dogs and cats. “The addition of Benefortin to our cardiology portfolio now enables us to provide veterinary practices with two of the cornerstones of canine CHF treatment, and the palatability1 of Benefortin makes it an excellent choice for vets needing to prescribe an ACE inhibitor,” comments Jemima Scott, Boehringer Ingelheim brand manager. To support the launch of Benefortin, Boehringer is offering veterinary practices the opportunity to win one of three Bosch microwave ovens in a prize draw by answering three multiple choice questions on the ACE inhibitor. For further information on Benefortin, please contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959. References 1 Report No. LA V-C-5003-11.3 UK VetTrak data – December 2011. Doses of Fortekor 2.5mg used in cats estimated from market research and removed from overall sales to compare products in the dog CHF market only.

More from


You might be interested in...